Cidel Asset Management Inc. Buys 90,170 Shares of Abbott Laboratories $ABT

Cidel Asset Management Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 28.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 412,395 shares of the healthcare product maker’s stock after buying an additional 90,170 shares during the period. Abbott Laboratories accounts for about 2.3% of Cidel Asset Management Inc.’s holdings, making the stock its 11th largest holding. Cidel Asset Management Inc.’s holdings in Abbott Laboratories were worth $42,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. J. Stern & Co. LLP grew its stake in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $2,938,892,000. Invesco Ltd. raised its position in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ninety One UK Ltd bought a new position in Abbott Laboratories in the 4th quarter worth about $336,815,000. Finally, Vanguard Group Inc. boosted its stake in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott was highlighted by TipRanks as one of three dividend aristocrat stocks Wall Street currently likes, reinforcing its appeal as a defensive, income-oriented name. 3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 23, 2026
• Positive Sentiment: Piper Sandler reaffirmed its Overweight rating and kept a $115 price target on Abbott, signaling meaningful upside from current levels. Benzinga report on Piper Sandler rating
• Positive Sentiment: Abbott’s Similac brand launched a new “Love Without Measure” campaign aimed at supporting parents and strengthening brand engagement in infant nutrition. Abbott (ABT) Launches Similac Campaign To Ease Social Media Pressure On Young Parents
• Positive Sentiment: Analysts continue to view Abbott favorably overall, with consensus still at “Moderate Buy,” which supports the stock’s recent rebound. Abbott Laboratories (NYSE:ABT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Several articles note that ABT has attracted investor attention, but these pieces are largely traffic-driven and do not add new fundamental information. Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Commentary on Abbott’s sharp year-to-date decline points to existing headwinds such as respiratory testing weakness, China uncertainty, and acquisition dilution, but does not introduce a new catalyst. How to Approach Abbott Stock Following Its Sharp YTD Decline?
• Negative Sentiment: A Missouri appeals court declined to elevate Abbott’s appeal of a $495 million preterm baby formula verdict, leaving a large legal liability in place and likely weighing on sentiment. Missouri appeals court won’t send Abbott’s appeal of $495 million preterm baby formula verdict to higher court

Insiders Place Their Bets

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $90.44 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $157.53 billion, a price-to-earnings ratio of 25.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63. The business has a 50-day simple moving average of $89.59 and a two-hundred day simple moving average of $105.93. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm posted $1.09 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 70.59%.

Analyst Ratings Changes

A number of analysts have weighed in on ABT shares. Piper Sandler restated an “overweight” rating and set a $115.00 price objective on shares of Abbott Laboratories in a research note on Monday. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, Citigroup lowered their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.